Activation of self-reactive CD4+ T cells plays a central role in the initiation and maintenance of autoimmune diseases. We recently reported that intravenous immunoglobulin (IVIg) inhibits the MHC II-restricted CD4+ T cell activation induced by the presentation of immune complexes. Because native antigens can also play a role in the induction of several autoimmune diseases, we determined whether IVIg could also affect CD4+ T cell activation following presentation of native antigens by APCs. Here we report that IVIg significantly reduces the activation of CD4+ T cells by native ovalbumin. The inhibitory effect is FcΓR-independent and occurs following internalization of IVIg inside APCs, where it interferes... More
Activation of self-reactive CD4+ T cells plays a central role in the initiation and maintenance of autoimmune diseases. We recently reported that intravenous immunoglobulin (IVIg) inhibits the MHC II-restricted CD4+ T cell activation induced by the presentation of immune complexes. Because native antigens can also play a role in the induction of several autoimmune diseases, we determined whether IVIg could also affect CD4+ T cell activation following presentation of native antigens by APCs. Here we report that IVIg significantly reduces the activation of CD4+ T cells by native ovalbumin. The inhibitory effect is FcΓR-independent and occurs following internalization of IVIg inside APCs, where it interferes with the intracellular events leading to MHC II-dependent antigen presentation. The effect of IVIg on native antigen presentation could therefore contribute to dampen the autoimmune reaction by reducing CD4+ T cell activation and the subsequent inflammatory response induced by these cells.
